As a global leader in pharmaceuticals and in-vitro diagnostics, Roche has cultivated a deep, enduring presence in Taiwan for decades. We consistently position ourselves not merely as a supplier of medicines and medical technologies, but as a steadfast strategic partner invested in the long-term success of Taiwan’s healthcare system. Today, as the Taiwanese government actively champions its ambitious “Healthy Taiwan” vision, Roche is more committed than ever to serving as a core catalyst for this vital initiative.

We firmly believe that true breakthroughs in public health require tight-knit collaboration among industry, government, and academia. By uniting top-tier global scientific insights with Taiwan’s exceptional local medical capabilities, we can effectively address unmet medical needs. Together, we can translate cutting-edge innovation into tangible, life-saving outcomes that safeguard the health and well-being of the Taiwanese people.

Fueling Taiwan’s Clinical Momentum: Expanding R&D Investment to Accelerate Patient Access to Innovative Medicines

Taiwan occupies a pivotal strategic position within the broader Asia-Pacific biomedical landscape. Its core driving force is an abundant, highly mature, and globally respected “clinical momentum.” Deeply recognizing this immense potential and the high caliber of local medical talent, Roche remains highly optimistic about Taiwan. Through concrete, sustained actions, we are fulfilling our long-term commitment to expand our local R&D footprint, striving to create more opportunities for patients to gain immediate access to innovative therapies.

Paving the Way for Patient Access: To build on this foundation, Roche invests over NT$100 million (US$3 million) into Taiwan’s local clinical research ecosystem annually. This financial commitment supports local clinical development and establishes a pathway for Taiwanese patients to access early-stage investigational medicines in alignment with global timelines.

As of May 2026, Roche actively manages over 80 ongoing clinical trials for innovative drugs across Taiwan. Through these clinical studies, we have helped over 2,000 participating patients gain early access to innovative treatments, addressing urgent medical needs through clinical trial pathways.

Leveraging Real-World Data to Champion Precision Medicine

Roche has taken the lead in Taiwan by providing approximately 2,000 comprehensive genomic profiling services. This invaluable repository of ‘local clinical data’ not only serves as a critical reference for physicians’ clinical decision-making but also contributes to the construction of a national genomic medicine big database. Leveraging this local real-world experience, Roche has provided essential data support to inform the policy decision of integrating next-generation sequencing (NGS) into the National Health Insurance (NHI) reimbursement scheme. This stands as a prime example of public-private partnership, driving policy upgrades through real-world evidence.

Optimizing Resource Structure: Fostering Sustainable Accessibility to Innovation

Standing at the critical crossroads of Taiwan’s journey to becoming an Asia-Pacific biomedical hub, we highly commend the government’s recent resolve in optimizing the healthcare environment. Innovative policies, such as the implementation of the Cancer Drugs Fund, demonstrate a clear commitment to improving patient access.

Building on this solid foundation, Roche actively advocates for the implementation of “Value-Based Healthcare.” We look forward to partnering with the government to continuously optimize pharmaceutical expenditure allocation and increase the reasonable proportion of innovative drugs within the overall healthcare budget. Looking at international benchmarks that foster innovation, spending on on-patent drugs accounts for approximately 50% of the pharmaceutical budget in Germany and Canada. Similarly, single-source drug expenditure reaches 60% in mature markets like Japan and Australia.

We earnestly hope Taiwan can establish sustainable innovation indicators. Doing so will not only ensure that patients continuously receive treatments synchronized with global standards but will also send a powerful, strategic message to the global pharmaceutical community: Taiwan is a high-quality biomedical environment that deeply values innovation and encourages long-term foreign investment.

Forging a Paradigm of Biomedical Innovation

Biomedical innovation is not a sprint; it is a marathon of sustainability. Cultivating a medical ecosystem that respects and is friendly to innovation cannot be accomplished by a single enterprise or government department alone. Roche firmly commits to working hand in hand with partners across Taiwan’s industry, government, and academia. Through transparent, constructive dialogue, we aim to construct a policy environment that balances innovative flexibility with financial sustainability. By aligning Roche’s global R&D momentum with Taiwan’s outstanding medical prowess, we can collectively establish Taiwan as a global paradigm of biomedical innovation.

M-TW-00008789